



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Human Papillomavirus Self-sampling for Cervical Cancer Screening among Women in sub-Saharan Africa: A Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-056140
Article Type:	Protocol
Date Submitted by the Author:	04-Aug-2021
Complete List of Authors:	dzobo, mathias; University of Pretoria Faculty of Health Sciences, School of Health Systems and Public Health Dzinamarira, Tafadzwa; University of Pretoria Faculty of Health Sciences, School of Health Systems and Public Health Kgarosi, Kabelo; University of Pretoria Faculty of Health Sciences, Department of Library Services Mashamba-Thompson, Tivani; University of Pretoria, Faculty of Health Sciences
Keywords:	Gynaecological oncology < GYNAECOLOGY, Molecular diagnostics < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Human Papillomavirus Self-sampling for Cervical Cancer Screening among Women in  
sub-Saharan Africa: A Scoping Review Protocol**

Mathias Dzobo<sup>1</sup>, Tafadzwa Dzinamarira<sup>1</sup>, Kabelo Kgarosi<sup>2</sup>, Tivani Mashamba-Thompson<sup>3</sup>

<sup>1</sup>School of Health Systems and Public Health, Faculty of Health Sciences, University of  
Pretoria, Pretoria, 0002, South Africa

<sup>2</sup>Department of Library Services, Faculty of Health Sciences, University of Pretoria, South  
Africa

<sup>3</sup>Faculty of Health Sciences, University of Pretoria, South Africa

Corresponding author:

Mathias Dzobo

School of Health Systems and Public Health, Faculty of Health Science, University of  
Pretoria, Pretoria, 0002, South Africa

Email: [mattdzb@gmail.com](mailto:mattdzb@gmail.com)

+263772995121

Manuscript Word Count: 3,099

## Abstract

## Introduction

Evidence shows that women in sub-Saharan Africa (SSA) have high rates of cervical cancer (CC) mortality compared to women in high-income countries (HICs). Effective screening programmes have significantly reduced the burden of CC in HICs. Human papillomavirus (HPV) self-sampling (HPVSS) has been reported to be an acceptable screening method among women in underserved communities. Here we outline a protocol for a scoping review aimed at mapping literature on the use and acceptability of HPVSS for screening CC in SSA to reveal gaps to guide future research and practice.

## Methods and Analysis

The scoping review protocol was developed according to Arksey and O'Malley and Levac *et al*, and guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). We will search Scopus, PubMed, EBSCOHost, and Web of Science databases for studies presenting evidence on HPVSS in SSA. We will search grey literature in the form of dissertations/theses, conference proceedings, websites of international organizations such as the World Health Organisation, and relevant government reports reporting evidence on HPVSS programs for screening CC among women in SSA. We will employ NVIVO version 12 software package to extract the relevant themes from the included articles. We will use the mixed method appraisal tool (MMAT) version 2018 to appraise the quality of the included studies.

1  
2  
3 44 **Ethics and dissemination**  
4

5  
6 45 No ethical approval is needed for the study as it will not include animals or human  
7  
8 46 participants. The results of the proposed scoping review will be disseminated electronically,  
9  
10 47 in print, and through conference presentations as well as key stakeholder meetings.  
11  
12

13  
14 48 **Keywords:** Women; Human papillomavirus DNA tests; Self-sampling; sub-Saharan Africa  
15  
16

17 49  
18  
19 50 **Article Summary**  
20  
21

22 51 **Strengths and Limitations of this study:**  
23  
24

- 25  
26 52 • The results of this review will establish a baseline understanding of the use of Human  
27  
28 53 papillomavirus self-sampling for cervical cancer screening in sub-Saharan Africa and  
29  
30 54 expose gaps that exist in cervical cancer screening in sub-Saharan Africa  
31  
32 55 • Here we propose the use of an established scoping review methodology with a  
33  
34 56 comprehensive search strategy that includes grey literature.  
35  
36 57 • The study will conduct a formal quality assessment of included studies guided by an  
37  
38 58 established mixed methods appraisal tool.  
39  
40 59 • A limitation of the review is the potential to miss relevant articles given that the  
41  
42 60 findings will be limited to articles written in English.  
43  
44  
45  
46

47 61 **Introduction**  
48  
49

50 62 Despite being a largely preventable disease, cervical cancer (CC) incidence and mortality  
51  
52 63 remain important indicators of global health inequality.<sup>1</sup> An estimated 90% of the globally  
53  
54 64 recorded CC-related deaths are in low-and middle-income countries (LMICs), of which 8 out  
55  
56 65 of 10 are recorded within the sub-Saharan African (SSA) region.<sup>2</sup> SSA bears the highest  
57  
58 66 burden of the human immunodeficiency virus (HIV) infection globally and the high  
59  
60

prevalence of HPV infection in this population further increases the burden of CC in SSA.<sup>3 4</sup>

CC screening has significantly reduced the burden of CC in high-income countries (HICs).<sup>3 5</sup>

However, in low-income countries, the burden of CC incidence and mortality is very high due to the lack of organised CC screening services and low uptake of available screening services by women.<sup>6-8</sup> Human papillomavirus (HPV) DNA testing on self-collected specimens has been shown to increase the participation of women in CC screening programmes by reducing individual and health system-related barriers to screening particularly in low-resource settings.<sup>9 10</sup> HPV self-sampling (HPVSS) is a process where a woman who wants to know whether she has a high-risk HPV infection uses a kit to collect a cervicovaginal sample from herself.<sup>9-11</sup>

Elimination of CC is an important component of sustainable development goals (SDGs) to tackle global health inequalities and non-communicable diseases.<sup>12</sup> In 2018 the World Health Organisation (WHO) made a global call for the elimination of CC by end of the century.<sup>13</sup> Under the call, The WHO targets to screen 70% of women with a high-performance test by 35, and again by 45 years of age by 2030.<sup>13</sup> The WHO has recommended the use of a high-performance test like HPV DNA test for the screening of CC in women.<sup>14</sup>

The burden of CC in SSA is profound and complex. HPVSS may be an effective means of ensuring screening services for underserved women who fail to access screening services due to a variety of reasons. Although HPVSS is established as an effective strategy for detecting CC by identifying women at risk, it is less clear whether this is an acceptable screening option for women in SSA. The purpose of this scoping review is to map the current literature on the use and acceptability of HPVSS as a primary screening method in SSA. It is anticipated that findings from this study will enable the researchers to identify gaps in the subject matter and guide future research towards improved and increased participation of women in CC screening programmes. The results of this study will also guide policymakers

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

92 in crafting programmes that increase access to CC screening services to underserved women  
93 in SSA.

For peer review only

## 94 **Methods and Analysis**

95 This proposed scoping review is part of a multi-phase Ph.D. study investigating the use and  
 96 acceptability of HPVSS for CC screening among women in SSA. The review will be  
 97 developed according to the methodological framework proposed by Arksey and O'Malley<sup>15</sup>  
 98 and Levac et al,<sup>16</sup> and guided by the Preferred Reporting Items for Systematic Reviews and  
 99 Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR).<sup>17</sup> According to Arksey and  
 100 O'Malley framework,<sup>15 16</sup> a scoping review follows five stages: (i) identify the research  
 101 question, (ii) identify relevant studies, (iii) select eligible studies, (iv) charting the data, and  
 102 (v) collating, summarising and reporting the results. Arksey and O'Malley also proposed an  
 103 optional sixth stage, the consultation with key stakeholders to provide insights beyond those  
 104 found in the literature. This scoping review will not include consultation with stakeholders.

### 105 **Eligibility of the research question for a scoping review**

106 The research question is: What is the evidence on the use and acceptability of HPVSS for CC  
 107 screening of women in SSA?

108 To determine the eligibility of the proposed research question for a scoping review, we used  
 109 the Population, Concept, and Context (PCC) nomenclature as depicted in Table 1.

110 **Table 1:** PCC for determining the eligibility of the research question.

<b>Population</b>	Asymptomatic females; 25 years and older residing in sub-Saharan Africa
<b>Concept</b>	HPV self-sampling programmes conducted between January 2011 and June 2021
<b>Context</b>	sub-Saharan Africa



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Identification of relevant studies**

We will conduct a comprehensive search of relevant literature from the following electronic databases for articles published between January 2011 and June 2021: Scopus, PubMed, EBSCOhost, and Web of Science. In addition, we will search on ResearchGate as well as grey literature from university dissertations and theses from institutional repositories, government, and international organizations’ reports such as the WHO. We will identify additional relevant studies by manually searching all references cited in the included studies to identify studies that have not been indexed by the electronic databases.

The comprehensive search strategy will be co-developed by the principal investigator (PI), subject specialist, and university librarian to ensure the correct use of indexing terminology and Medical Subject Headings (MeSH) terms. The following keywords or MeSH terms will be used: 1) “cervical cancer” 2) “human papillomavirus” 3) “self-sampling” 4) “sub-Saharan Africa”. Keywords may be refined to suit each database. Each search will be documented in detail showing the keywords/MeSH terms, date of search, electronic database, and the number of retrieved studies. We piloted the search strategy on one of the electronic databases and the results of the search are presented in Table 2.

Table 2: Results of pilot search in PubMed.

Date of search	Electronic Database	Keywords/MeSH terms	Number of retrieved studies
05/07/2021	Pubmed	(((("Uterine Cervical Neoplasms"[Mesh] OR "Uterine Cervical Neoplasm*"[tw] OR "Cervical Cancer"[tw] AND (female[Filter]))) OR ("Alphapapillomavirus"[Mesh] OR Alphapapillomavirus[tw] OR "Human papillomavirus*"[tw] OR HPV[tw] OR papillomavirus*"[tw] AND (female[Filter]))) AND ("Self Administration"[Mesh] OR self-sampl*[tw] OR "self collect*"[tw] OR "self Administ*"[tw] OR "self screen*"[tw] AND (female[Filter]))) AND ("Africa South of the Sahara"[Mesh] OR "Africa Sub-Saharan"[tw] OR "Subsaharan Africa"[tw] OR "Sub-Sahara africa"[tw] AND (female[Filter])) Filters: in the last 10 years, Female	117

### Selection of eligible studies

Relevant studies will be selected using the following criteria:

#### *Inclusion criteria*

- Articles reporting on evidence of HPVSS in women 25 years and older

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 141 • Articles reporting on evidence of HPVSS in women residing in SSA
- 142 • Articles published between January 2011 and June 2021

143 ***Exclusion criteria***

144 Articles will be excluded from the scoping review if they have the following characteristics:

- 145 • Articles that report on other methods of CC screening
- 146 • Articles reporting on evidence of HPVSS in women residing outside SSA
- 147 • Articles published before January 2011 and after June 2021
- 148 • Review articles
- 149 • Articles that are written in other languages other than English

150 All eligible articles will be exported to an Endnote 20 library and duplicates will be removed.

151 The articles will be screened in two stages, namely abstract and full article screening. The PI  
152 will screen titles and abstracts in parallel with the co-reviewer. After screening titles and  
153 abstracts, the reviewers will discuss any discrepancies in selected articles until a consensus is  
154 reached. Two independent reviewers will then screen the full texts of articles selected during  
155 the first stage. A third screener will resolve any discrepancies in selected articles after the  
156 full-text screening. Both abstract and full article screening will be guided by the above  
157 inclusion/exclusion criteria.

158 The level of agreement between screeners' results after screening abstracts and full articles  
159 will be determined by calculating Cohen's kappa statistic. The kappa statistic will be  
160 interpreted as follows: values < 0.1 indicate no agreement and 0.10-0.20 indicate none to  
161 slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1.00 as  
162 almost perfect agreement. We will report the screening results following the Preferred

163 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines<sup>18</sup> (Figure  
164 1).

### 165 **Charting the data**

166 We developed a data charting form to capture information from each relevant study. Two  
167 independent reviewers will pilot the data charting form before commencing with the scoping  
168 review. The data charting form will be modified based on the reviewers' feedback and it will  
169 constantly be updated throughout the scoping review. The form that will be used for data  
170 charting is presented in Table 3.

172 **Table 3:** Data charting form.

Author & year of publication
Publication journal
Title of study
Aim of study
Study population
Study setting
Geography (SSA country where the study was conducted)
Number of women (sample size)
Age of women
Study design
Method of delivery of self-sampling kits (home-based or hospital-based)
Main findings
Other significant findings

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Collating, summarizing, and reporting the results**

We will employ NVivo version 12 to conduct content thematic analysis of the included studies. We will present a narrative account of the findings presenting the main concepts from the included articles in line with our research question.

**Quality appraisal**

We will use the mixed method appraisal tool (MMAT) version 2018 to evaluate the quality of the included studies.<sup>19</sup> Two independent reviewers will carry out the quality appraisal process. The following percentage scores will be used to grade the quality of evidence: i) ≤50% will represent low quality evidence ii) 51-75% will represent average quality evidence iii) 76-100% will represent high-quality evidence. This quality appraisal method will enable us to appraise a variety of study methods, i.e. qualitative, quantitative or mixed methods studies.<sup>19</sup>

**Ethical considerations**

No ethical approval is needed for the study because it will not include animals or human participants.

**Patient and public involvement**

In this protocol, there was no involvement of patients and the public.

**Discussion**

The elimination of CC is in line with the 2030 agenda for SDG 3 and targets that seek to ensure healthy lives and promote well-being for all at all ages.<sup>12</sup> The majority of women in LMICs including SSA lack access to CC screening services and where the services are available they are underutilised due to several barriers.<sup>5</sup> HPVSS has been demonstrated to be an acceptable screening method for underserved women that increases their participation in

1  
2  
3 197 CC screening programmes.<sup>20</sup> There have been several HPVSS interventions that have been  
4  
5 198 conducted in SSA, however, a few studies have synthesised evidence on the acceptability of  
6  
7 199 the intervention.<sup>21</sup> The proposed scoping review will map evidence on the use and  
8  
9 200 acceptability of HPVSS in SSA. Getting prior information on studies conducted in SSA will  
10  
11 201 help guide the implementation of HPVSS for CC screening in the region. The scoping review  
12  
13 202 is part of a larger study that seeks to pilot an HPVSS programme for CC screening in  
14  
15 203 Zimbabwe. This intervention has the potential to increase access to underserved women as  
16  
17 204 well as increase their participation in CC screening.  
18  
19  
20  
21  
22  
23

24 206 In this scoping review, we will include evidence on the use of HPVSS for screening women  
25  
26 207 aged 25 years and older, the WHO recommends HPV testing for women aged 30 years and  
27  
28 208 above because most HPV infections in young women are transient.<sup>14</sup> We have chosen to  
29  
30 209 include studies published in the last decade (2011-2021) to capture recent evidence on  
31  
32 210 HPVSS in SSA. In addition, the WHO recommended the use of HPV testing for CC  
33  
34 211 screening in 2013,<sup>14</sup> therefore, we are likely to find studies where HPVSS interventions have  
35  
36 212 been implemented in SSA in response to the WHO recommendation. Furthermore, studies  
37  
38 213 reporting evidence on other methods of CC screening other than HPVSS will not be  
39  
40 214 considered for this review as well as studies conducted outside SSA. We have chosen to map  
41  
42 215 evidence on HPVSS in SSA because it has the highest burden of CC in the world and  
43  
44 216 findings are more likely to apply to Zimbabwe which is a country in SSA.  
45  
46  
47  
48  
49

50 217 We anticipate finding relevant studies reporting on the use of HPVSS for screening CC in  
51  
52 218 SSA. The findings of this review may be of importance to policymakers involved in  
53  
54 219 designing interventions to increase access to CC screening services to underserved women.  
55  
56  
57 220 Furthermore, the findings will guide further research on best practices of implementing an  
58  
59  
60

1  
2  
3 221 HPVSS programme in low-resource settings. This review will be disseminated electronically  
4  
5 222 or in print and presented at scientific conferences.  
6  
7  
8 223 *Abbreviations*  
9  
10  
11 224 **CC:** Cervical cancer  
12  
13  
14 225 **HPV:** Human papillomavirus  
15  
16  
17 226 **HPVSS:** Human papillomavirus self-sampling  
18  
19  
20 227 **LMICs:** Low middle-income countries  
21  
22  
23 228 **MeSH:** Medical Subject Headings  
24  
25  
26 229 **MMAT:** Mixed method appraisal tool  
27  
28  
29 230 **PRISMA-ScR:** Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
30  
31 231 extension for scoping review  
32  
33  
34 232 **SSA:** sub-Saharan Africa  
35  
36  
37 233 **Declarations**  
38  
39  
40 234 *Acknowledgements*  
41  
42  
43 235 The authors would like to extend their appreciation to the University of  
44  
45  
46 236 Pretoria (UP) Systematic Review Service for supporting the development  
47  
48  
49 237 of this research study.  
50  
51  
52 238 *Funding*  
53  
54  
55 239 This research received no specific grant from any funding agency in the public, commercial  
56  
57 240 or not-for-profit sectors.  
58  
59  
60

241 *Availability of data and materials*

242 All data generated or analysed during this study will be included in the scoping review  
243 article.

244 *Author Contributions*

245 MD conceptualized the study and prepared the draft proposal under the supervision of TPM-  
246 T. MD, TD, and TPM-T contributed to the development of the background and planned the  
247 output of the research as well as the design of the study. KK contributed to the development  
248 of the search strategy. MD prepared the manuscript, and TD and TPM-T critically reviewed  
249 it. All authors (MD, TD, KK and TPM-T) contributed to the reviewed draft version of the  
250 manuscript and approved the final version.

251 *Ethics approval and consent to participate*

252 Not applicable.

253 *Consent for publication*

254 Not applicable.

255 *Competing interests*

256 None declared.

257

258 **References**

- 259 1. Ginsburg O, Bray F, Coleman MP, et al. The global burden of women's cancers: a grand challenge  
260 in global health. *The Lancet* 2017;389(10071):847-60.
- 261 2. Kuguyo O, Matimba A, Tsikai N, et al. Cervical cancer in Zimbabwe: a situation analysis. *The Pan*  
262 *African Medical Journal* 2017;27




1  
2  
3 263 3. Johnson LG, Armstrong A, Joyce CM, et al. Implementation strategies to improve cervical cancer  
4  
5 264 prevention in sub-Saharan Africa: a systematic review. *Implementation Science* 2018;13(1):1-  
6  
7 265 18.  
8  
9 266 4. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, et al. Infrastructure requirements for human  
10  
11 267 papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. *Vaccine*  
12  
13 268 2013;31:F47-F52.  
14  
15 269 5. McFarland DM, Gueldner SM, Mogobe KD. Integrated review of barriers to cervical cancer  
16  
17 270 screening in sub-Saharan Africa. *Journal of Nursing Scholarship* 2016;48(5):490-98.  
18  
19 271 6. Runge AS, Bernstein ME, Lucas AN, et al. Cervical cancer in Tanzania: a systematic review of  
20  
21 272 current challenges in six domains. *Gynecologic oncology reports* 2019;29:40-47.  
22  
23 273 7. Lim JN, Ojo AA. Barriers to utilisation of cervical cancer screening in Sub Sahara Africa: a  
24  
25 274 systematic review. *European journal of cancer care* 2017;26(1):e12444.  
26  
27 275 8. Black E, Hyslop F, Richmond R. Barriers and facilitators to uptake of cervical cancer screening  
28  
29 276 among women in Uganda: a systematic review. *BMC women's health* 2019;19(1):1-12.  
30  
31 277 9. Nakisige C, Trawin J, Mitchell-Foster S, et al. Integrated cervical cancer screening in Mayuge  
32  
33 278 District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol.  
34  
35 279 *BMC public health* 2020;20(1):1-13.  
36  
37 280 10. Defo VF, Domgue JF. Why Consider Self-Sampling for Cervical Cancer Screening in Low-and  
38  
39 281 Middle-Income Countries? *AMA journal of ethics* 2020;22(2):116-25.  
40  
41 282 11. Yeh PT, Kennedy CE, De Vuyst H, et al. Self-sampling for human papillomavirus (HPV) testing:  
42  
43 283 a systematic review and meta-analysis. *BMJ global health* 2019;4(3):e001351.  
44  
45 284 12. Resolution A. RES/70/1. Transforming our world: the 2030 agenda for sustainable development.  
46  
47 285 *Seventieth United Nations General Assembly, New York* 2015;25  
48  
49 286 13. Call W. Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem.  
50  
51 287 Geneva, Switzerland: WHO; 2019.  
52  
53 288 14. Organization WH. WHO guidelines for screening and treatment of precancerous lesions for  
54  
55 289 cervical cancer prevention: World Health Organization 2013.  
56  
57  
58  
59  
60

15. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International journal of social research methodology* 2005;8(1):19-32.
16. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implementation science* 2010;5(1):1-9.
17. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Annals of internal medicine* 2018;169(7):467-73.
18. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Bmj* 2021;372
19. Hong QN, Fàbregues S, Bartlett G, et al. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. *Education for Information* 2018;34(4):285-91.
20. Styffe C, Tratt E, Macdonald ME, et al. HPV self-sampling in Indigenous communities: a scoping review. *Journal of immigrant and minority health* 2019:1-8.
21. Nodjikuambaye ZA, Adawaye C, Mboumba Bouassa RS, et al. A systematic review of self-sampling for HPV testing in Africa. *International Journal of Gynecology & Obstetrics* 2020;149(2):123-29.

**Figure 1:** PRISMA flow diagram of the study selection process

Figure. 1



Total studies included in review  
(n = )  
Reports of total included studies  
(n = )

PRISMA flow diagram of the study selection process

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist

Section and topic	Item No	Checklist item	Page number
<b>ADMINISTRATIVE INFORMATION</b>			
Title:		<b>Human Papillomavirus Self-sampling for Cervical Cancer Screening among Women in sub-Saharan Africa: A Scoping Review Protocol</b>	
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	N/A
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	8
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	8
Sponsor	5b	Provide name for the review funder and/or sponsor	8
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	8
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	3
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
<b>METHODS</b>			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4-6
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	4-5
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	5

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	5-6
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	5-6
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	6
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	4
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	6
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	N/A
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	N/A
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	N/A
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	N/A
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	6-7
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	N/A
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	N/A

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

# BMJ Open

## Human Papillomavirus Self-sampling for Cervical Cancer Screening among Women in sub-Saharan Africa: A Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-056140.R1
Article Type:	Protocol
Date Submitted by the Author:	23-Mar-2022
Complete List of Authors:	Dzobo, Mathias; University of Pretoria Faculty of Health Sciences, School of Health Systems and Public Health Dzinamarira, Tafadzwa; University of Pretoria Faculty of Health Sciences, School of Health Systems and Public Health Kgarosi, Kabelo; University of Pretoria Faculty of Health Sciences, Department of Library Services Mashamba-Thompson, Tivani; University of Pretoria, Faculty of Health Sciences
<b>Primary Subject Heading</b>:	Research methods
Secondary Subject Heading:	Diagnostics, Health policy, Research methods, Sexual health, Global health
Keywords:	Gynaecological oncology < GYNAECOLOGY, Molecular diagnostics < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts





## 21 Abstract

## 22 Introduction

23 Evidence shows that women in sub-Saharan Africa have high rates of cervical cancer (CC)  
24 mortality compared to women in high-income countries. Effective screening programmes  
25 have significantly reduced the burden of CC in high-income countries. Self-sampling for  
26 Human papillomavirus testing (HPVSS) has been reported to increase the participation and  
27 engagement of women in CC screening. Before HPVSS can be introduced for CC screening  
28 there is a need to establish its acceptability among end-users to ensure the increase in CC  
29 screening rates. Here we outline a protocol for a scoping review aimed at mapping literature  
30 on the use and acceptability of HPVSS for screening CC in sub-Saharan Africa to reveal gaps  
31 to guide future research and practice.

## 32 Method

33 The scoping review protocol was developed according to Arksey and O'Malley and Levac *et*  
34 *al*, and guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
35 Extension for Scoping Reviews. We will search Scopus, PubMed, Medline Ovid, Cochrane,  
36 and Web of Science databases for evidence on the use and acceptability of HPVSS published  
37 between January 2011 and July 2021. We will also search grey literature in the form of  
38 dissertations/theses, conference proceedings, websites of international organizations such as  
39 the World Health Organisation, and relevant government reports reporting evidence on  
40 HPVSS programs for screening CC among women in sub-Saharan Africa.

## 41 Ethics and dissemination

1  
2  
3 42 No ethical approval is needed for the study as it will not include animals or human  
4  
5 43 participants. The results of the proposed scoping review will be disseminated electronically in  
6  
7 44 peer-reviewed journals, in print, and through conference presentations.  
8  
9

10 45 **Keywords:** Women; Human papillomavirus DNA tests; Self-sampling; cervical cancer, sub-  
11  
12  
13 46 Saharan Africa  
14  
15

16 47 **Article Summary**  
17

18  
19 48 **Strengths and Limitations of this study:**  
20

- 21  
22 49 • The results of this review will establish a baseline understanding of the use and  
23  
24 50 acceptability of HPVSS for CC screening in SSA and expose gaps that exist  
25  
26 51 • Here we propose the use of an established scoping review methodology with a  
27  
28 52 comprehensive search strategy that includes grey literature.  
29  
30 53 • The study will conduct a formal quality assessment of included studies guided by an  
31  
32 54 established mixed methods appraisal tool.  
33  
34 55 • A limitation of the review is the potential to miss relevant articles given that review  
35  
36 56 articles will not be considered for the study  
37  
38  
39  
40

41 57 **Introduction**  
42

43  
44 58 Despite being a largely preventable disease, cervical cancer (CC) incidence and mortality  
45  
46 59 remain important indicators of global health inequality.<sup>1</sup> An estimated 90% of the globally  
47  
48 60 recorded CC-related deaths are in low-and middle-income countries (LMICs), of which 8 out  
49  
50 61 of 10 are recorded within the sub-Saharan African (SSA) region.<sup>2</sup> In addition, the high  
51  
52 62 burden of HIV/AIDS further worsens the problem of CC in SSA.<sup>3 4</sup> CC screening has  
53  
54 63 significantly reduced the burden of CC in high-income countries (HICs).<sup>3 5</sup> However, in low-  
55  
56 64 and middle-income countries (LMICs), the burden of CC incidence and mortality is very high  
57  
58  
59  
60

1  
2  
3 65 due to the lack of organised CC screening services and low uptake of available screening  
4  
5 66 services by women.<sup>6-8</sup> In 2018 the World Health Organisation (WHO) made a global call for  
6  
7 67 the elimination of CC by end of the century.<sup>9</sup> Under the call, The WHO targets to screen 70%  
8  
9 68 of women with a high-performance test by 35, and again by 45 years of age by 2030.<sup>9</sup> The  
10  
11 69 WHO has recommended the use of a high-performance test like Human papillomavirus  
12  
13 70 (HPV) DNA test for the screening of CC in women <sup>10</sup> and recent WHO guidelines now  
14  
15 71 advocate for the use of self-sampling to screen CC among women.<sup>11</sup>  
16  
17  
18  
19  
20 72 Self-sampling for HPV testing (HPVSS) is a process where a woman who wants to know  
21  
22 73 whether she has a high-risk HPV infection uses a kit to collect a cervicovaginal sample from  
23  
24 74 herself.<sup>12-14</sup> HPVSS has been shown to increase the participation of women in CC screening  
25  
26 75 programmes by reducing individual and health system-related barriers to screening  
27  
28 76 particularly in low-resource settings.<sup>12 14</sup> The lack of privacy, fear and shame of a pelvic  
29  
30 77 exam and long distances to health facilities have been cited as barriers to CC screening.<sup>8 12</sup>  
31  
32  
33 78 Important considerations for introducing HPVSS should consider the follow-up of women  
34  
35 79 who screen positive for HPV as well as triage options with another method such as visual  
36  
37 80 inspection with acetic acid to prevent overtreatment of HPV infections which in most cases  
38  
39 81 are transient.<sup>12 13</sup> Before HPVSS can be incorporated into national screening programmes  
40  
41 82 there is a need to determine its acceptability among the targeted end-users.  
42  
43  
44  
45  
46 83 The purpose of this scoping review is to map the literature evidence on the use and  
47  
48 84 acceptability of HPVSS as a primary screening method in SSA. It is anticipated that findings  
49  
50 85 from this study will enable the researchers to identify research gaps and guide future research  
51  
52 86 towards improved and increased participation of women in CC screening programmes. The  
53  
54 87 results of this study will also guide policymakers in designing CC screening programmes  
55  
56 88 based on HPVSS that are more acceptable to end-users to increase the uptake of CC  
57  
58 89 screening services in SSA.  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

90   **Methods and Analysis**

91   This proposed scoping review is part of a multi-phase Ph.D. study investigating the use and

92   acceptability of HPVSS for CC screening among women in SSA. The review will be

93   developed according to the methodological framework proposed by Arksey and O’Malley<sup>15</sup>

94   and Levac et al,<sup>16</sup> and guided by the Preferred Reporting Items for Systematic Reviews and

95   Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR).<sup>17</sup> According to Arksey and

96   O’Malley framework,<sup>15 16</sup> a scoping review follows five stages: (i) identify the research

97   question, (ii) identify relevant studies, (iii) select eligible studies, (iv) charting the data, and

98   (v) collating, summarising and reporting the results. Arksey and O’Malley also proposed an

99   optional sixth stage, the consultation with key stakeholders to provide insights beyond those

100   found in the literature. This scoping review will not include consultation with stakeholders.

101   **Eligibility of the research question for a scoping review**

102   The research question is: What is the evidence on the use and acceptability of HPVSS for CC

103   screening of women in SSA?

104   The main objective is: To map out evidence on the use and acceptability of HPVSS for CC

105   screening of women in SSA.

106   We used the following key elements To determine the eligibility of the proposed research

107   question for a scoping review, We used the following elements: (Population, Concept, and

108   Context) to conceptualize the review question as depicted in Table 1.

109   **Table 1:** PCC for determining the eligibility of the research question.

110   

<b>Population</b>	Asymptomatic females; 25 years and older residing in SSA
<b>Concept</b>	HPVSS programmes conducted between January 2011 and June 2021
<b>Context</b>	Countries in the SSA region

## 110 Identification of relevant studies

111 We will conduct a comprehensive search of relevant literature from the following electronic  
112 databases for articles published between January 2011 and June 2021: Scopus, PubMed,  
113 Medline Ovid, Cochrane, and Web of Science databases. We will search for randomized  
114 controlled trials, non-randomized controlled trials, and observational studies that reported  
115 evidence on HPVSS for CC screening. Review articles (narrative, scoping, systematic, meta-  
116 analysis, and meta-synthesis) were excluded. In addition, we will search for grey literature  
117 from university dissertations and theses from institutional repositories, government, and  
118 international organizations' reports such as the WHO. We will identify additional relevant  
119 studies by manually searching all references cited in the included studies to identify studies  
120 that have not been indexed by the electronic databases. The authors of the included articles  
121 will be contacted for missing data and review articles will not be included in this study.

122 The comprehensive search strategy will be co-developed by the principal investigator (PI),  
123 subject specialist, and university librarian to ensure the correct use of indexing terminology  
124 and Medical Subject Headings (MeSH) terms. The following keywords or MeSH terms will  
125 be used: 1) "cervical cancer" 2) "human papillomavirus" 3) "self-sampling" 4) "sub-Saharan  
126 Africa". Keywords may be refined to suit each database. Each search will be documented in  
127 detail showing the keywords/MeSH terms, date of search, electronic database, and the  
128 number of retrieved studies. We piloted the search strategy on all the electronic databases and  
129 the results of the search are presented in Supplementary File 1.

## 130 Selection of eligible studies

131 Relevant studies will be selected using the following criteria:

### 132 Inclusion criteria

- 133 • Articles reporting on evidence of HPVSS in women 25 years and older

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- Articles reporting on the acceptability of HPVSS for CC screening
- Articles reporting on evidence of HPVSS in women residing in SSA
- Articles published between January 2011 and June 2021

**Exclusion criteria**

Articles will be excluded from the scoping review if they have the following characteristics:

- Articles that report on other methods of CC screening articles that do not report on acceptability, willingness, or preferences for HPVSS
- Articles reporting on evidence of HPVSS in women residing outside SSA
- Articles published before January 2011 and after June 2021
- Review articles

All eligible articles will be exported to an Endnote 20 library and duplicates will be removed.

The articles will be screened in three stages, namely title, abstract and full article screening.

The PI will screen titles and abstracts in parallel with the co-reviewer. After screening titles and abstracts, the reviewers will discuss any discrepancies in selected articles until a consensus is reached. Two independent reviewers will then screen the full texts of articles selected during the first stage. A third screener will resolve any discrepancies in selected articles after the full-text screening. Both abstract and full article screening will be guided by the above inclusion/exclusion criteria.

The level of agreement between screeners' results after screening abstracts and full articles will be determined by calculating Cohen's kappa statistic. The kappa statistic will be interpreted as follows: values < 0.1 indicate no agreement and 0.10-0.20 indicate none to slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1.00 as almost perfect agreement. We will report the screening results following the Preferred

157 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines<sup>18</sup> (Figure  
158 1).

## 159 Charting the data

160 We developed a data charting form to capture information from each relevant study. Two  
161 independent reviewers will pilot the data charting form before commencing with the scoping  
162 review. The data charting form will be modified based on the reviewers' feedback and it will  
163 constantly be updated throughout the scoping review. The form that will be used for data  
164 charting is presented in Table 2.

165 **Table 2.** Data charting form.

Author & year of publication
Aim of study
Study population
Study setting (rural or urban)
Geography (SSA country where the study was conducted)
Number of women (sample size)
Age of women
Study design
Setting of self-sampling kits (health facility or home/community based)
Type of self-sampling device used
Main findings (acceptability of HPVSS)
Other significant findings

## 167 Collating, summarizing, and reporting the results

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

We will employ NVivo version 12 to extract themes from the included studies. We will conduct a content thematic analysis of the included studies. We will present a narrative account of the findings presenting the main concepts from the included articles in line with our research question. Our study context is acceptability of self-sampling for HPV testing which is defined as the ease and comfort or willingness to perform cervicovaginal self-sampling<sup>19</sup>

**Quality appraisal**

We will use the mixed method appraisal tool (MMAT) version 2018 to evaluate the quality of the included studies.<sup>20</sup> Two independent reviewers will carry out the quality appraisal process. The following percentage scores will be used to grade the quality of evidence: i) ≤50% will represent low quality evidence ii) 51-75% will represent average quality evidence iii) 76-100% will represent high-quality evidence. This quality appraisal method will enable us to appraise a variety of study methods, i.e. qualitative, quantitative or mixed methods studies.<sup>20</sup>

**Ethics and dissemination**

No ethical approval is needed for the study because it will not include animals or human participants. The findings of this review will be disseminated electronically in peer-reviewed journals or print and presented at scientific conferences.

**Patient and public involvement**

In this protocol, there was no involvement of patients and the public.

**Discussion**

The elimination of CC is in line with the 2030 agenda for SDG 3 and targets that seek to ensure healthy lives and promote well-being for all at all ages.<sup>21</sup> The majority of women in



LMICs including SSA lack access to CC screening services and where the services are available they are underutilised due to several barriers.<sup>5</sup> HPVSS has been demonstrated to be an acceptable screening method for underserved women that increases their participation and engagement in CC screening programmes.<sup>22</sup> There have been several HPVSS interventions that have been conducted in SSA, however, a few studies have synthesised evidence on the acceptability of the intervention.<sup>23</sup> The proposed scoping review will map evidence on the use and acceptability of HPVSS in SSA. Getting prior information on studies conducted in SSA will help guide the implementation of HPVSS for CC screening in the region and other LMICs. The scoping review is part of a larger study that seeks to pilot an HPVSS programme for CC screening in Zimbabwe. The scoping review will synthesise existing literature evidence and reveal gaps in research and guide the methodology of the main study. This intervention has the potential to increase access to underserved women as well as increase their participation in CC screening.

In this scoping review, we will include evidence on the use and acceptability of HPVSS for screening women aged 25 years and older, the WHO recommends HPV testing for women aged 30 years and above because most HPV infections in young women are transient.<sup>10</sup> We have chosen to include studies published in the last decade (2011-2021) to capture recent evidence on HPVSS in SSA. In addition, the WHO recommended the use of HPV testing for CC screening in 2013,<sup>10</sup> therefore, we are likely to find studies where HPVSS interventions have been implemented in SSA in response to the WHO recommendation. Furthermore, studies reporting evidence on other methods of CC screening other than HPVSS will not be considered for this review as well as studies conducted outside SSA. A limitation of the review is the potential to miss relevant articles given that review articles will not be

1  
2  
3 215 considered for the study and also the potential to miss important studies from other LMICs  
4  
5  
6 216 outside SSA.  
7  
8  
9 217 We have chosen to map evidence on HPVSS in SSA because it has the highest burden of CC  
10  
11 218 in the world and findings are more likely to apply to Zimbabwe which is a country in SSA.  
12  
13 219 We anticipate finding relevant studies reporting on the use and acceptability of HPVSS for  
14  
15 220 screening CC in SSA. The findings of this review will help policymakers to design  
16  
17 221 interventions that increase the uptake of CC screening services in SSA. Furthermore, the  
18  
19  
20 222 findings will guide further research on best practices of implementing an acceptable HPVSS  
21  
22 223 programme in LMICs.  
23  
24  
25 224 *Abbreviations*  
26  
27  
28 225 **CC:** Cervical cancer  
29  
30  
31 226 **HPV:** Human papillomavirus  
32  
33  
34 227 **HPVSS:** Human papillomavirus self-sampling  
35  
36  
37 228 **LMICs:** Low middle-income countries  
38  
39  
40 229 **MeSH:** Medical Subject Headings  
41  
42  
43 230 **MMAT:** Mixed method appraisal tool  
44  
45  
46 231 **PRISMA-ScR:** Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
47  
48 232 extension for scoping review  
49  
50  
51 233 **SSA:** sub-Saharan Africa  
52  
53  
54 234 **Declarations**  
55  
56  
57 235 *Acknowledgements*  
58  
59  
60 236 The authors would like to extend their appreciation to the University of

237 Pretoria (UP) Systematic Review Service for supporting the development

238 of this research study.

#### 239 *Funding*

240 This research received no specific grant from any funding agency in the public, commercial  
241 or not-for-profit sectors.

#### 242 *Author Contributions*

243 MD conceptualized the study and prepared the draft proposal under the supervision of TPM-  
244 T. MD, TD, and TPM-T contributed to the development of the background and planned the  
245 output of the research as well as the design of the study. KK contributed to the development  
246 of the search strategy. MD prepared the manuscript, and TD and TPM-T critically reviewed  
247 it. All authors (MD, TD, KK, and TPM-T) contributed to the reviewed draft version of the  
248 manuscript and approved the final version.

#### 249 *Ethics approval and consent to participate*

250 Not applicable.

#### 251 *Consent for publication*

252 Not applicable.

#### 253 *Competing interests*

254 None declared.

255

#### 256 **References**


- 257 1. Ginsburg O, Bray F, Coleman MP, et al. The global burden of women's cancers: a grand challenge  
258 in global health. *The Lancet* 2017;389(10071):847-60.

- 259 2. Kuguyo O, Matimba A, Tsikai N, et al. Cervical cancer in Zimbabwe: a situation analysis. *The Pan*
- 260 *African Medical Journal* 2017;27
- 261 3. Johnson LG, Armstrong A, Joyce CM, et al. Implementation strategies to improve cervical cancer
- 262 prevention in sub-Saharan Africa: a systematic review. *Implementation Science* 2018;13(1):1-
- 263 18.
- 264 4. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, et al. Infrastructure requirements for human
- 265 papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. *Vaccine*
- 266 2013;31:F47-F52.
- 267 5. McFarland DM, Gueldner SM, Mogobe KD. Integrated review of barriers to cervical cancer
- 268 screening in sub-Saharan Africa. *Journal of Nursing Scholarship* 2016;48(5):490-98.
- 269 6. Runge AS, Bernstein ME, Lucas AN, et al. Cervical cancer in Tanzania: a systematic review of
- 270 current challenges in six domains. *Gynecologic oncology reports* 2019;29:40-47.
- 271 7. Lim JN, Ojo AA. Barriers to utilisation of cervical cancer screening in Sub Sahara Africa: a
- 272 systematic review. *European journal of cancer care* 2017;26(1):e12444.
- 273 8. Black E, Hyslop F, Richmond R. Barriers and facilitators to uptake of cervical cancer screening
- 274 among women in Uganda: a systematic review. *BMC women's health* 2019;19(1):1-12.
- 275 9. Call W. Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem.
- 276 Geneva, Switzerland: WHO; 2019.
- 277 10. Organization WH. WHO guidelines for screening and treatment of precancerous lesions for
- 278 cervical cancer prevention: World Health Organization 2013.
- 279 11. Organisation WH. WHO Guideline on self-care interventions for health and well-being (W.H.O)
- 280 World Health Organisation [Available from:
- 281 <https://www.who.int/publications/i/item/9789240030909> accessed 15 December 2021
- 282 2021.
- 283 12. Defo VF, Domgue JF. Why Consider Self-Sampling for Cervical Cancer Screening in Low-and
- 284 Middle-Income Countries? *AMA journal of ethics* 2020;22(2):116-25.
- 285 13. Yeh PT, Kennedy CE, De Vuyst H, et al. Self-sampling for human papillomavirus (HPV) testing: a
- 286 systematic review and meta-analysis. *BMJ global health* 2019;4(3):e001351.
- 287 14. Nakisige C, Trawin J, Mitchell-Foster S, et al. Integrated cervical cancer screening in Mayuge
- 288 District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol.
- 289 *BMC public health* 2020;20(1):1-13.
- 290 15. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International*
- 291 *journal of social research methodology* 2005;8(1):19-32.
- 292 16. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implementation*
- 293 *science* 2010;5(1):1-9.
- 294 17. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist
- 295 and explanation. *Annals of internal medicine* 2018;169(7):467-73.
- 296 18. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for
- 297 reporting systematic reviews. *Bmj* 2021;372
- 298 19. Kohler RE, Elliott T, Monare B, et al. HPV self-sampling acceptability and preferences among
- 299 women living with HIV in Botswana. *Int J Gynaecol Obstet* 2019;147(3):332-38.
- 300 20. Hong QN, Fàbregues S, Bartlett G, et al. The Mixed Methods Appraisal Tool (MMAT) version 2018
- 301 for information professionals and researchers. *Education for Information* 2018;34(4):285-91.
- 302 21. Resolution A. RES/70/1. Transforming our world: the 2030 agenda for sustainable development.
- 303 *Seventieth United Nations General Assembly, New York* 2015;25
- 304 22. Styffe C, Tratt E, Macdonald ME, et al. HPV self-sampling in Indigenous communities: a scoping
- 305 review. *Journal of immigrant and minority health* 2019:1-8.
- 306 23. Nodjikoumbaye ZA, Adawaye C, Mboumba Bouassa RS, et al. A systematic review of
- 307 self-sampling for HPV testing in Africa. *International Journal of Gynecology & Obstetrics*
- 308 2020;149(2):123-29.

310 **Figure 1:** PRISMA flow diagram of the study selection process

For peer review only

Figure. 1



PRISMA flow diagram of the study selection process

**Supplementary File 1:** Results of the search strategy for electronic databases and grey literature

Date of search	Electronic Database	Keywords/MeSH terms
14-06-2021	Web of Science	Human papillomavirus*" OR alphapapillomavirus OR hpv OR papillomavirus* OR "Cervical cancer*" OR "Uterine Cervical Neoplasm*" OR "cancer of the cervix" OR "uterine cervix tumor" AND "self-sampling" OR "self sampl*" OR "self collect*" OR "self screen*" OR screening AND Africa OR "sub-Saharan Africa" OR "Africa South of the Sahara" AND female OR woman OR women NOT algeria OR egypt OR libya OR morocco OR tunisia
06-07-2021	PubMed	((("Uterine Cervical Neoplasms"[Mesh] OR "Uterine Cervical Neoplasm*" [tw] OR "Cervical Cancer" [tw] AND (female[Filter]))) OR ("Alphapapillomavirus"[Mesh] OR Alphapapillomavirus[tw] OR "Human papillomavirus*" [tw] OR HPV[tw] OR papillomavirus* [tw] AND (female[Filter]))) AND ("Self Administration"[Mesh] OR self-sampl* [tw] OR "self collect*" [tw] OR "self Administ*" [tw] OR "self screen*" [tw] AND (female[Filter]))) AND ("Africa South of the Sahara"[Mesh] OR "Africa Sub-Saharan" [tw] OR "Subsaharan Africa" [tw] OR "Sub-Sahara africa" [tw] AND (female[Filter])) Filters: in the last 10 years, Female
06-07-2021	Scopus	(TITLE-ABS-KEY(Africa* OR "sub-Saharan Africa" OR SS OR "Africa South of the Sahara" OR "Subsahara* Africa") AND TITLE-ABS-KEY("Human papillomavirus*" OR alphapapillomavirus OR hpv OR papillomavirus* OR "Cervical cancer*" OR "Uterine Cervical Neoplasm*" OR "cancer of the cervix" OR "uterine cervix tumor") AND TITLE-ABS-KEY("self-sampling" OR "self sampl*" OR "self collect*" OR "self screen*" OR screening) AND NOT TITLE-ABS-KEY(Algeria OR Egypt OR Libya OR Morocco OR Tunisia)) AND ( LIMIT-TO ( PUBYEAR,2021) OR LIMIT-TO ( PUBYEAR,2020) OR LIMIT-TO ( PUBYEAR,2019) OR LIMIT-TO ( PUBYEAR,2018) OR LIMIT-TO ( PUBYEAR,2017) OR LIMIT-TO ( PUBYEAR,2016) OR LIMIT-TO ( PUBYEAR,2015) OR LIMIT-TO ( PUBYEAR,2014) OR LIMIT-TO ( PUBYEAR,2013) OR LIMIT-TO ( PUBYEAR,2012) OR LIMIT-TO ( PUBYEAR,2011) ) AND ( LIMIT-TO ( SRCTYPE,"j" ) )
12-07-2021	Ovid Medline	Ovid MEDLINE(R) <1996 to August Week 3 2021> 1 exp Uterine Cervical Neoplasms/ 48683 2 Uterine Cervical Neoplasms.af. 48719 3 Cervical Cancer.af. 37377 4 exp Alphapapillomavirus/ 8338 5 Alphapapillomavirus.af. 2733 6 exp Papillomavirus Infections/ 31367 7 Papillomavirus Infection*.af. 28075

		<div>8 Human papillomavirus*.af. 33426</div> <div>9 HPV.af. 35627</div> <div>10 papillomavirus*.af. 42280</div> <div>11 Cervi* Cancer.af. 38169</div> <div>12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 86646</div> <div>13 exp Self Administration/ 8841</div> <div>14 Self Administration.af. 11764</div> <div>15 self-sampl*.af. 682</div> <div>16 self collect*.af. 1155</div> <div>17 self administrat*.af. 12471</div> <div>18 self screen*.af. 205</div> <div>19 self-testing.af. 1129</div> <div>20 self-test*.af. 1491</div> <div>21 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 15594</div> <div>22 exp "Africa South of the Sahara"/ 168852</div> <div>23 sub-sahara* Africa.af. 19913</div> <div>24 22 or 23 173452</div> <div>25 12 and 21 and 24 101</div> <div>26 limit 25 to yr="2011 -Current" 95</div> <div>27 limit 26 to (female and humans)95</div>
14-07-2021	Cochrane	<div>ID Search Hits</div> <div>#1 MeSH descriptor: [Alphapapillomavirus] explode all trees 247</div> <div>#2 MeSH descriptor: [Uterine Cervical Neoplasms] explode all trees 2171</div> <div>#3 ("Uterine Cervical Neoplasm*" OR "Cervical Cancer" OR Alphapapillomavirus OR "Human papillomavirus*" OR HPV OR papillomavirus*) (Word variations have been searched) 7022</div> <div>#4 #1 OR #2 OR #3 6989</div> <div>#5 MeSH descriptor: [Self Administration] explode all trees 778</div> <div>#6 (self-sampl* OR "self collect*" OR "self Administ*" OR "self screen*") (Word variations have been searched) 6495</div> <div>#7 #5 OR #6 1040</div> <div>#8 MeSH descriptor: [Africa South of the Sahara] explode all trees 6811</div> <div>#9 ("sub-Saharan Africa") (Word variations have been searched) 2037</div> <div>#10 #8 OR #9 8279</div> <div>#11 #4 AND #7 AND #10 8</div> <div>Date range 2011-2021 Results 7</div>
31-08-21	Grey Literature identified through other sources	"Human papillomavirus" OR "cervical cancer" AND "self-sampling" AND "sub-Saharan Africa"



For peer review only

## Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
<b>TITLE</b>			
Title	1	<b>Human Papillomavirus Self-sampling for Cervical Cancer Screening among Women in sub-Saharan Africa: A Scoping Review Protocol</b>	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	4
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	4-5
<b>METHODS</b>			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	N/A
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	7
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	7
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	6
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	10

Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	10
----------------------	----	--	----

For peer review only



**St. Michael's**

Inspired Care.  
Inspiring Science.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
<b>RESULTS</b>			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	9
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	N/A
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	10
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	N/A
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	N/A
<b>DISCUSSION</b>			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	11
Limitations	20	Discuss the limitations of the scoping review process.	11
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	12
<b>FUNDING</b>			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	13

JB1 = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

\* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169:467–473. doi: 10.7326/M18-0850.

# BMJ Open

## Human Papillomavirus Self-sampling for Cervical Cancer Screening among Women in sub-Saharan Africa: A Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-056140.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Apr-2022
Complete List of Authors:	Dzobo, Mathias; University of Pretoria Faculty of Health Sciences, School of Health Systems and Public Health Dzinamarira, Tafadzwa; University of Pretoria Faculty of Health Sciences, School of Health Systems and Public Health Kgarosi, Kabelo; University of Pretoria Faculty of Health Sciences, Department of Library Services Mashamba-Thompson, Tivani; University of Pretoria, Faculty of Health Sciences
<b>Primary Subject Heading</b>:	Research methods
Secondary Subject Heading:	Diagnostics, Health policy, Research methods, Sexual health, Global health
Keywords:	Gynaecological oncology < GYNAECOLOGY, Molecular diagnostics < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1     **Human Papillomavirus Self-sampling for Cervical Cancer Screening among Women in**  
2     **sub-Saharan Africa: A Scoping Review Protocol**  
3     Mathias Dzobo<sup>1</sup>, Tafadzwa Dzinamarira<sup>1</sup>, Kabelo Kgarosi<sup>2</sup>, Tivani Mashamba-Thompson<sup>3</sup>  
4     <sup>1</sup>School of Health Systems and Public Health, Faculty of Health Sciences, University of  
5     Pretoria, Pretoria, 0002, South Africa  
6     <sup>2</sup>Department of Library Services, Faculty of Health Sciences, University of Pretoria, South  
7     Africa  
8     <sup>3</sup>Faculty of Health Sciences, University of Pretoria, South Africa  
9  
10    Corresponding author:  
11    Mathias Dzobo  
12    School of Health Systems and Public Health, Faculty of Health Science, University of  
13    Pretoria, Pretoria, 0002, South Africa  
14    Email: [mattdzb@gmail.com](mailto:mattdzb@gmail.com)  
15    +263772995121  
16  
17  
18    Manuscript Word Count: 2, 355 words  
19  
20

## 21 Abstract

## 22 Introduction

23 Evidence shows that women in sub-Saharan Africa have high rates of cervical cancer (CC)  
24 mortality compared to women in high-income countries. Effective screening programmes  
25 have significantly reduced the burden of CC in high-income countries. Self-sampling for  
26 Human papillomavirus testing (HPVSS) has been reported to increase the participation and  
27 engagement of women in CC screening. Before HPVSS can be introduced for CC screening  
28 there is a need to establish its acceptability among end-users to ensure the increase in CC  
29 screening rates. Here we outline a protocol for a scoping review aimed at mapping literature  
30 on the use and acceptability of HPVSS for screening CC in sub-Saharan Africa to reveal gaps  
31 to guide future research and practice.

## 32 Method

33 The scoping review protocol was developed according to Arksey and O'Malley and Levac *et*  
34 *al*, and guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
35 Extension for Scoping Reviews. We will search Scopus, PubMed, Medline Ovid, Cochrane,  
36 and Web of Science databases for evidence on the use and acceptability of HPVSS published  
37 between January 2011 and July 2021. We will also search grey literature in the form of  
38 dissertations/theses, conference proceedings, websites of international organizations such as  
39 the World Health Organisation, and relevant government reports reporting evidence on  
40 HPVSS programs for screening CC among women in sub-Saharan Africa.

## 41 Ethics and dissemination

1  
2  
3 42 No ethical approval is needed for the study as it will not include animals or human  
4  
5 43 participants. The results of the proposed scoping review will be disseminated electronically in  
6  
7 44 peer-reviewed journals, in print, and through conference presentations.  
8  
9

10 45 **Keywords:** Women; Human papillomavirus DNA tests; Self-sampling; cervical cancer, sub-  
11  
12  
13 46 Saharan Africa  
14  
15

16 47 **Article Summary**  
17  
18

19 48 **Strengths and Limitations of this study:**  
20  
21

- 22 49 • The results of this review will establish a baseline understanding of the use and  
23  
24 50 acceptability of HPVSS for CC screening in SSA and expose gaps that exist  
25  
26 51 • Here we propose the use of an established scoping review methodology with a  
27  
28 52 comprehensive search strategy that includes grey literature.  
29  
30 53 • The study will conduct a formal quality assessment of included studies guided by an  
31  
32 54 established mixed methods appraisal tool.  
33  
34 55 • A limitation of the review is the potential to miss relevant articles given that review  
35  
36 56 articles will not be considered for the study  
37  
38  
39  
40

41 57 **Introduction**  
42  
43

44 58 Despite being a largely preventable disease, cervical cancer (CC) incidence and mortality  
45  
46 59 remain important indicators of global health inequality.<sup>1</sup> An estimated 90% of the globally  
47  
48 60 recorded CC-related deaths are in low-and middle-income countries (LMICs), of which 8 out  
49  
50 61 of 10 are recorded within the sub-Saharan African (SSA) region.<sup>2</sup> In addition, the high  
51  
52 62 burden of HIV/AIDS further worsens the problem of CC in SSA.<sup>3 4</sup> CC screening has  
53  
54 63 significantly reduced the burden of CC in high-income countries (HICs).<sup>3 5</sup> However, in low-  
55  
56 64 and middle-income countries (LMICs), the burden of CC incidence and mortality is very high  
57  
58  
59  
60



1  
2  
3 65 due to the lack of organised CC screening services and low uptake of available screening  
4  
5 66 services by women.<sup>6-8</sup> In 2018 the World Health Organisation (WHO) made a global call for  
6  
7 67 the elimination of CC by end of the century.<sup>9</sup> Under the call, The WHO targets to screen 70%  
8  
9 68 of women with a high-performance test by 35, and again by 45 years of age by 2030.<sup>9</sup> The  
10  
11 69 WHO has recommended the use of a high-performance test like Human papillomavirus  
12  
13 70 (HPV) DNA test for the screening of CC in women <sup>10</sup> and recent WHO guidelines now  
14  
15 71 advocate for the use of self-sampling to screen CC among women.<sup>11</sup>  
16  
17  
18  
19  
20 72 Self-sampling for HPV testing (HPVSS) is a process where a woman who wants to know  
21  
22 73 whether she has a high-risk HPV infection uses a kit to collect a cervicovaginal sample from  
23  
24 74 herself.<sup>12-14</sup> HPVSS has been shown to increase the participation of women in CC screening  
25  
26 75 programmes by reducing individual and health system-related barriers to screening  
27  
28 76 particularly in low-resource settings.<sup>12 14</sup> The lack of privacy, fear and shame of a pelvic  
29  
30 77 exam, and long distances to health facilities have been cited as barriers to CC screening.<sup>8 12</sup>  
31  
32  
33 78 Important considerations for introducing HPVSS should consider the follow-up of women  
34  
35 79 who screen positive for HPV as well as triage options with another method such as visual  
36  
37 80 inspection with acetic acid to prevent overtreatment of HPV infections which in most cases  
38  
39 81 are transient.<sup>12 13</sup> Before HPVSS can be incorporated into national screening programmes  
40  
41 82 there is a need to determine its acceptability among the targeted end-users.  
42  
43  
44  
45  
46 83 Findings from a systematic review by Tesfahunei et al revealed the effectiveness of HPVSS  
47  
48 84 to increase CC screening uptake by women in SSA compared to standard clinician  
49  
50 85 sampling<sup>15</sup>. However, the systematic review only considered randomised control trials and  
51  
52 86 hence perceptions and experiences of women could not be explored. There is a need to map  
53  
54 87 existing evidence on the acceptability of HPVSS by synthesising both quantitative and  
55  
56 88 qualitative data as well as studies that employ a mixed-methods approach.  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

89 The purpose of this scoping review is to map the literature evidence on the use and  
90 acceptability of HPVSS for CC screening in SSA by synthesising data from quantitative and  
91 qualitative studies. It is anticipated that findings from this study will enable the researchers to  
92 identify research gaps and guide future research towards improved and increased  
93 participation of women in CC screening programmes. The results of this study will also guide  
94 policymakers in designing CC screening programmes based on HPVSS that are more  
95 acceptable to end-users to increase the uptake of CC screening services in SSA.

For peer review only

## 96 **Methods and Analysis**

97 This proposed scoping review is part of a multi-phase Ph.D. study investigating the use and  
 98 acceptability of HPVSS for CC screening among women in SSA. The review will be  
 99 developed according to the methodological framework proposed by Arksey and O'Malley<sup>16</sup>  
 100 and Levac et al,<sup>17</sup> and guided by the Preferred Reporting Items for Systematic Reviews and  
 101 Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR).<sup>18</sup> According to Arksey and  
 102 O'Malley framework,<sup>16 17</sup> a scoping review follows five stages: (i) identify the research  
 103 question, (ii) identify relevant studies, (iii) select eligible studies, (iv) charting the data, and  
 104 (v) collating, summarising and reporting the results. Arksey and O'Malley also proposed an  
 105 optional sixth stage, the consultation with key stakeholders to provide insights beyond those  
 106 found in the literature. This scoping review will not include consultation with stakeholders.

### 107 **Eligibility of the research question for a scoping review**

108 The research question is: What is the evidence on the use and acceptability of HPVSS for CC  
 109 screening of women in SSA?

110 The main objective is: To map out evidence on the use and acceptability of HPVSS for CC  
 111 screening of women in SSA.

112 We used the following elements: (Population, Concept, and Context) to conceptualize the  
 113 review question as depicted in Table 1.

114 **Table 1:** PCC for determining the eligibility of the research question.

<b>Population</b>	Asymptomatic females; 25 years and older residing in SSA
<b>Concept</b>	HPVSS programmes conducted between January 2011 and June 2021
<b>Context</b>	Countries in the SSA region

### 115 **Identification of relevant studies**

1  
2  
3 116 We will conduct a comprehensive search of relevant literature from the following electronic  
4  
5 117 databases for articles published between January 2011 and June 2021: Scopus, PubMed,  
6  
7 118 Medline Ovid, Cochrane, and Web of Science databases. We will search for randomized  
8  
9 119 controlled trials, non-randomized controlled trials, and observational studies that reported  
10  
11 120 evidence on HPVSS for CC screening. Review articles (narrative, scoping, systematic, meta-  
12  
13 121 analysis, and meta-synthesis) were excluded. In addition, we will search for grey literature  
14  
15 122 from university dissertations and theses from institutional repositories, government, and  
16  
17 123 international organizations' reports such as the WHO. We will identify additional relevant  
18  
19 124 studies by manually searching all references cited in the included studies to identify studies  
20  
21 125 that have not been indexed by the electronic databases. The authors of the included articles  
22  
23 126 will be contacted for missing data and review articles will not be included in this study.  
24  
25  
26  
27  
28  
29 127 The comprehensive search strategy will be co-developed by the principal investigator (PI),  
30  
31 128 subject specialist, and university librarian to ensure the correct use of indexing terminology  
32  
33 129 and Medical Subject Headings (MeSH) terms. The following keywords or MeSH terms will  
34  
35 130 be used: 1) "cervical cancer" 2) "human papillomavirus" 3) "self-sampling" 4) "sub-Saharan  
36  
37 131 Africa". Keywords may be refined to suit each database. Each search will be documented in  
38  
39 132 detail showing the keywords/MeSH terms, date of search, electronic database, and the  
40  
41 133 number of retrieved studies. We piloted the search strategy on all the electronic databases and  
42  
43 134 the results of the search are presented in Supplementary File 1.  
44  
45  
46  
47

48 135 **Selection of eligible studies**

49  
50  
51 136 Relevant studies will be selected using the following criteria:

52  
53  
54 137 ***Inclusion criteria***

- 55  
56  
57 138 • Articles reporting on evidence of HPVSS in women 25 years and older  
58  
59 139 • Articles reporting on the acceptability of HPVSS for CC screening  
60

140 • Articles reporting on evidence of HPVSS in women residing in SSA

141 • Articles published between January 2011 and June 2021

142 ***Exclusion criteria***

143 Articles will be excluded from the scoping review if they have the following characteristics:

144 • Articles that report on other methods of CC screening articles that do not report on

145 acceptability, willingness, or preferences for HPVSS

146 • Articles reporting on evidence of HPVSS in women residing outside SSA

147 • Articles published before January 2011 and after June 2021

148 • Review articles

149 All eligible articles will be exported to an Endnote 20 library and duplicates will be removed.

150 The articles will be screened in three stages, namely title, abstract and full article screening.

151 The PI will screen titles and abstracts in parallel with the co-reviewer. After screening titles

152 and abstracts, the reviewers will discuss any discrepancies in selected articles until a

153 consensus is reached. Two independent reviewers will then screen the full texts of articles

154 selected during the first stage. A third screener will resolve any discrepancies in selected

155 articles after the full-text screening. Both abstract and full article screening will be guided by

156 the above inclusion/exclusion criteria.

157 The level of agreement between screeners' results after screening abstracts and full articles

158 will be determined by calculating Cohen's kappa statistic. The kappa statistic will be

159 interpreted as follows: values < 0.1 indicate no agreement and 0.10-0.20 indicate none to

160 slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1.00 as

161 almost perfect agreement. We will report the screening results following the Preferred

162 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines<sup>19</sup> (Figure

163 1).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

164     **Charting the data**

165     We developed a data charting form to capture information from each relevant study. Two

166     independent reviewers will pilot the data charting form before commencing with the scoping

167     review. The data charting form will be modified based on the reviewers’ feedback and it will

168     constantly be updated throughout the scoping review. The form that will be used for data

169     charting is presented in Table 2.

170     **Table 2.** Data charting form.

Author & year of publication
Aim of study
Study population
Study setting (rural or urban)
Geography (SSA country where the study was conducted)
Number of women (sample size)
Age of women
Study design
Setting of self-sampling kits (health facility or home/community based)
Type of self-sampling device used
Main findings (acceptability of HPVSS)
Other significant findings

171

172     **Collating, summarizing, and reporting the results**

173     We will employ NVivo version 12 to extract themes from the included studies. We will

174     conduct a content thematic analysis of the included studies. We will present a narrative

175     account of the findings presenting the main concepts from the included articles in line with

176 our research question. Our study context is acceptability of self-sampling for HPV testing  
177 which is defined as the ease and comfort or willingness to perform cervicovaginal self-  
178 sampling<sup>20</sup>

### 179 **Quality appraisal**

180 We will use the mixed method appraisal tool (MMAT) version 2018 to evaluate the quality of  
181 the included studies.<sup>21</sup> Two independent reviewers will carry out the quality appraisal  
182 process. The following percentage scores will be used to grade the quality of evidence: i)  
183  $\leq 50\%$  will represent low quality evidence ii) 51-75% will represent average quality evidence  
184 iii) 76-100% will represent high-quality evidence. This quality appraisal method will enable  
185 us to appraise a variety of study methods, i.e. qualitative, quantitative or mixed methods  
186 studies.<sup>21</sup>

### 187 **Ethics and dissemination**

188 No ethical approval is needed for the study because it will not include animals or human  
189 participants. The findings of this review will be disseminated electronically in peer-reviewed  
190 journals or print and presented at scientific conferences.

### 191 **Patient and public involvement**

192 In this protocol, there was no involvement of patients and the public.

### 193 **Discussion**

194 The elimination of CC is in line with the 2030 agenda for SDG 3 and targets that seek to  
195 ensure healthy lives and promote well-being for all at all ages.<sup>22</sup> The majority of women in  
196 LMICs including SSA lack access to CC screening services and where the services are  
197 available they are underutilised due to several barriers.<sup>5</sup> HPVSS has been demonstrated to  
198 increases the participation and engagement of under-screened and unscreened women in CC

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

screening programmes.<sup>23</sup> There have been several HPVSS interventions that have been conducted in SSA, however, a few studies have synthesised evidence on the acceptability of the intervention.<sup>24</sup> The proposed scoping review will map evidence on the use and acceptability of HPVSS in SSA. Getting prior information on studies conducted in SSA will help guide the implementation of HPVSS for CC screening in the region and other LMICs. The scoping review is part of a larger study that seeks to pilot an HPVSS programme for CC screening in Zimbabwe. The scoping review will synthesise existing literature evidence and reveal gaps in research and guide the methodology of the main study. This intervention has the potential to increase access to underserved women as well as increase their participation in CC screening.

In this scoping review, we will include evidence on the use and acceptability of HPVSS for screening women aged 25 years and older, the WHO recommends HPV testing for women aged 30 years and above because most HPV infections in young women are transient.<sup>10</sup> We have chosen to include studies published in the last decade (2011-2021) to capture recent evidence on HPVSS in SSA. In addition, the WHO recommended the use of HPV testing for CC screening in 2013,<sup>10</sup> therefore, we are likely to find studies where HPVSS interventions have been implemented in SSA in response to the WHO recommendation. Furthermore, studies reporting evidence on other methods of CC screening other than HPVSS will not be considered for this review as well as studies conducted outside SSA. A limitation of the review is the potential to miss relevant articles given that review articles will not be considered for the study and also the potential to miss important studies from other LMICs outside SSA.

We have chosen to map evidence on HPVSS in SSA because it has the highest burden of CC in the world and findings are more likely to apply to Zimbabwe which is a country in SSA.



224 We anticipate finding relevant studies reporting on the use and acceptability of HPVSS for  
225 screening CC in SSA. The findings of this review will help policymakers to design  
226 interventions that increase the uptake of CC screening services in SSA. Furthermore, the  
227 findings will guide further research on best practices of implementing an acceptable HPVSS  
228 programme in LMICs.

#### 229 *Abbreviations*

230 **CC:** Cervical cancer

231 **HPV:** Human papillomavirus

232 **HPVSS:** Human papillomavirus self-sampling

233 **LMICs:** Low middle-income countries

234 **MeSH:** Medical Subject Headings

235 **MMAT:** Mixed method appraisal tool

236 **PRISMA-ScR:** Preferred Reporting Items for Systematic Reviews and Meta-Analyses

237 extension for scoping review

238 **SSA:** sub-Saharan Africa

#### 239 **Declarations**

#### 240 *Acknowledgements*

241 The authors would like to extend their appreciation to the University of  
242 Pretoria (UP) Systematic Review Service for supporting the development  
243 of this research study.

#### 244 *Funding*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

245 This research received no specific grant from any funding agency in the public, commercial  
246 or not-for-profit sectors.

247 *Author Contributions*

248 MD conceptualized the study and prepared the draft proposal under the supervision of TPM-  
249 T. MD, TD, and TPM-T contributed to the development of the background and planned the  
250 output of the research as well as the design of the study. KK contributed to the development  
251 of the search strategy. MD prepared the manuscript, and TD and TPM-T critically reviewed  
252 it. All authors (MD, TD, KK, and TPM-T) contributed to the reviewed draft version of the  
253 manuscript and approved the final version.

254 *Ethics approval and consent to participate*

255 Not applicable.

256 *Consent for publication*

257 Not applicable.

258 *Competing interests*


259 None declared.

261 **References**

262 1. Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: a grand challenge  
263 in global health. *The Lancet* 2017;389(10071):847-60.  
264 2. Kuguyo O, Matimba A, Tsikai N, et al. Cervical cancer in Zimbabwe: a situation analysis. *The Pan*  
265 *African Medical Journal* 2017;27  
266 3. Johnson LG, Armstrong A, Joyce CM, et al. Implementation strategies to improve cervical cancer  
267 prevention in sub-Saharan Africa: a systematic review. *Implementation Science* 2018;13(1):1-  
268 18.  
269 4. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, et al. Infrastructure requirements for human  
270 papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. *Vaccine*  
271 2013;31:F47-F52.

5. McFarland DM, Gueldner SM, Mogobe KD. Integrated review of barriers to cervical cancer screening in sub-Saharan Africa. *Journal of Nursing Scholarship* 2016;48(5):490-98.
6. Runge AS, Bernstein ME, Lucas AN, et al. Cervical cancer in Tanzania: a systematic review of current challenges in six domains. *Gynecologic oncology reports* 2019;29:40-47.
7. Lim JN, Ojo AA. Barriers to utilisation of cervical cancer screening in Sub Sahara Africa: a systematic review. *European journal of cancer care* 2017;26(1):e12444.
8. Black E, Hyslop F, Richmond R. Barriers and facilitators to uptake of cervical cancer screening among women in Uganda: a systematic review. *BMC women's health* 2019;19(1):1-12.
9. Call W. Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. Geneva, Switzerland: WHO; 2019.
10. Organization WH. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention: World Health Organization 2013.
11. Organisation WH. WHO Guideline on self-care interventions for health and well-being (W.H.O) World Health Organisation [Available from: <https://www.who.int/publications/i/item/9789240030909> accessed 15 December 2021 2021.
12. Defo VF, Domgue JF. Why Consider Self-Sampling for Cervical Cancer Screening in Low-and Middle-Income Countries? *AMA journal of ethics* 2020;22(2):116-25.
13. Yeh PT, Kennedy CE, De Vuyst H, et al. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. *BMJ global health* 2019;4(3):e001351.
14. Nakisige C, Trawin J, Mitchell-Foster S, et al. Integrated cervical cancer screening in Mayuge District Uganda (ASPIRE Mayuge): a pragmatic sequential cluster randomized trial protocol. *BMC public health* 2020;20(1):1-13.
15. Tesfahune HA, Ghebreyesus MS, Assefa DG, et al. Human papillomavirus self-sampling versus standard clinician-sampling for cervical cancer screening in sub-Saharan Africa: a systematic review and meta-analysis of randomized controlled trials. *Infectious Agents and Cancer* 2021;16(1):43. doi: 10.1186/s13027-021-00380-5
16. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International journal of social research methodology* 2005;8(1):19-32.
17. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implementation science* 2010;5(1):1-9.
18. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Annals of internal medicine* 2018;169(7):467-73.
19. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Bmj* 2021;372
20. Kohler RE, Elliott T, Monare B, et al. HPV self-sampling acceptability and preferences among women living with HIV in Botswana. *Int J Gynaecol Obstet* 2019;147(3):332-38.
21. Hong QN, Fàbregues S, Bartlett G, et al. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. *Education for Information* 2018;34(4):285-91.
22. Resolution A. RES/70/1. Transforming our world: the 2030 agenda for sustainable development. *Seventieth United Nations General Assembly, New York* 2015;25
23. Styffe C, Tratt E, Macdonald ME, et al. HPV self-sampling in Indigenous communities: a scoping review. *Journal of immigrant and minority health* 2019:1-8.
24. Nodjikoambaye ZA, Adawaye C, Mboumba Bouassa RS, et al. A systematic review of self-sampling for HPV testing in Africa. *International Journal of Gynecology & Obstetrics* 2020;149(2):123-29.

Figure. 1



PRISMA flow diagram of the study selection process

**Supplementary File 1:** Results of the search strategy for electronic databases and grey literature

Date of search	Electronic Database	Keywords/MeSH terms
14-06-2021	Web of Science	Human papillomavirus*" OR alphapapillomavirus OR hpv OR papillomavirus* OR "Cervical cancer*" OR "Uterine Cervical Neoplasm*" OR "cancer of the cervix" OR "uterine cervix tumor" AND "self-sampling" OR "self sampl*" OR "self collect*" OR "self screen*" OR screening AND Africa OR "sub-Saharan Africa" OR "Africa South of the Sahara" AND female OR woman OR women NOT algeria OR egypt OR libya OR morocco OR tunisia
06-07-2021	PubMed	((("Uterine Cervical Neoplasms"[Mesh] OR "Uterine Cervical Neoplasm*" [tw] OR "Cervical Cancer" [tw] AND (female[Filter]))) OR ("Alphapapillomavirus"[Mesh] OR Alphapapillomavirus[tw] OR "Human papillomavirus*" [tw] OR HPV[tw] OR papillomavirus* [tw] AND (female[Filter]))) AND ("Self Administration"[Mesh] OR self-sampl* [tw] OR "self collect*" [tw] OR "self Administ*" [tw] OR "self screen*" [tw] AND (female[Filter]))) AND ("Africa South of the Sahara"[Mesh] OR "Africa Sub-Saharan" [tw] OR "Subsaharan Africa" [tw] OR "Sub-Sahara africa" [tw] AND (female[Filter])) Filters: in the last 10 years, Female
06-07-2021	Scopus	(TITLE-ABS-KEY(Africa* OR "sub-Saharan Africa" OR SS OR "Africa South of the Sahara" OR "Subsahara* Africa") AND TITLE-ABS-KEY("Human papillomavirus*" OR alphapapillomavirus OR hpv OR papillomavirus* OR "Cervical cancer*" OR "Uterine Cervical Neoplasm*" OR "cancer of the cervix" OR "uterine cervix tumor") AND TITLE-ABS-KEY("self-sampling" OR "self sampl*" OR "self collect*" OR "self screen*" OR screening) AND NOT TITLE-ABS-KEY(Algeria OR Egypt OR Libya OR Morocco OR Tunisia)) AND ( LIMIT-TO ( PUBYEAR,2021) OR LIMIT-TO ( PUBYEAR,2020) OR LIMIT-TO ( PUBYEAR,2019) OR LIMIT-TO ( PUBYEAR,2018) OR LIMIT-TO ( PUBYEAR,2017) OR LIMIT-TO ( PUBYEAR,2016) OR LIMIT-TO ( PUBYEAR,2015) OR LIMIT-TO ( PUBYEAR,2014) OR LIMIT-TO ( PUBYEAR,2013) OR LIMIT-TO ( PUBYEAR,2012) OR LIMIT-TO ( PUBYEAR,2011) ) AND ( LIMIT-TO ( SRCTYPE,"j" ) )
12-07-2021	Ovid Medline	Ovid MEDLINE(R) <1996 to August Week 3 2021> 1 exp Uterine Cervical Neoplasms/ 48683 2 Uterine Cervical Neoplasms.af. 48719 3 Cervical Cancer.af. 37377 4 exp Alphapapillomavirus/ 8338 5 Alphapapillomavirus.af. 2733 6 exp Papillomavirus Infections/ 31367 7 Papillomavirus Infection*.af. 28075

		8 Human papillomavirus*.af. 33426 9 HPV.af. 35627 10 papillomavirus*.af. 42280 11 Cervi* Cancer.af. 38169 12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 86646 13 exp Self Administration/ 8841 14 Self Administration.af. 11764 15 self-sampl*.af. 682 16 self collect*.af. 1155 17 self administrat*.af. 12471 18 self screen*.af. 205 19 self-testing.af. 1129 20 self-test*.af. 1491 21 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 15594 22 exp "Africa South of the Sahara"/ 168852 23 sub-sahara* Africa.af. 19913 24 22 or 23 173452 25 12 and 21 and 24 101 26 limit 25 to yr="2011 -Current" 95 27 limit 26 to (female and humans)95
14-07-2021	Cochrane	ID Search Hits #1 MeSH descriptor: [Alphapapillomavirus] explode all trees 247 #2 MeSH descriptor: [Uterine Cervical Neoplasms] explode all trees 2171 #3 ("Uterine Cervical Neoplasm*" OR "Cervical Cancer" OR Alphapapillomavirus OR "Human papillomavirus*" OR HPV OR papillomavirus*) (Word variations have been searched) 7022 #4 #1 OR #2 OR #3 6989 #5 MeSH descriptor: [Self Administration] explode all trees 778 #6 (self-sampl* OR "self collect*" OR "self Administ*" OR "self screen*") (Word variations have been searched) 6495 #7 #5 OR #6 1040 #8 MeSH descriptor: [Africa South of the Sahara] explode all trees 6811 #9 ("sub-Saharan Africa") (Word variations have been searched) 2037 #10 #8 OR #9 8279 #11 #4 AND #7 AND #10 8 Date range 2011-2021 Results 7
31-08-21	Grey Literature identified through other sources	"Human papillomavirus" OR "cervical cancer" AND "self-sampling" AND "sub-Saharan Africa"

For peer review only

## Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
<b>TITLE</b>			
Title	1	<b>Human Papillomavirus Self-sampling for Cervical Cancer Screening among Women in sub-Saharan Africa: A Scoping Review Protocol</b>	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	4
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	4-5
<b>METHODS</b>			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	N/A
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	7
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	7
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	6
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	10



Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	10
----------------------	----	--	----

For peer review only



SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
<b>RESULTS</b>			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	9
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	N/A
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	10
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	N/A
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	N/A
<b>DISCUSSION</b>			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	11
Limitations	20	Discuss the limitations of the scoping review process.	11
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	12
<b>FUNDING</b>			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	13

JB1 = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

\* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169:467–473. doi: 10.7326/M18-0850.